Scinai Immunotherapeutics Ltd.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Jerusalem, Israel
SCNI chart
What traders are saying about $SCNI
Latest postsScinai Immunotherapeutics Ltd. news
- Scinai Immunotherapeutics Ltd. Estimates – NASDAQ:SCNI
TradingView ·
- 12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga ·
- Scinai Immunotherapeutics Reports 300% Surge in CDMO Orders, $5.3 Million Financing, and Extended Runway
citybuzz - ·
- Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing
Yahoo Finance ·
- Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
Yahoo Finance ·
- Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
Yahoo Finance ·
- Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Yahoo Finance ·
- Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Yahoo Finance ·
- Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Yahoo Finance ·
- Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Yahoo Finance ·
- Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Yahoo Finance ·
- Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
Yahoo Finance ·
Scinai Immunotherapeutics Ltd. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $1.3M | $658,000 | – | – |
| Net income | -$8.3M | $4.8M | -$6.5M | -$5.8M |
| Diluted EPS | – | – | $0.00 | $0.01 |
| Total assets (year end) | $11.6M | $13.4M | $17.5M | $27.1M |
| Cash and equivalents (year end) | $1.7M | $2.0M | $4.9M | $14.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
About Scinai Immunotherapeutics Ltd.
- Ticker
- SCNI (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Jerusalem, Israel
- Incorporated in
- Israel
- Fiscal year end
- December 31
- SEC CIK
- 1611747
- Former names
- BiondVax Pharmaceuticals Ltd.
Frequently asked questions
What exchange is Scinai Immunotherapeutics Ltd. listed on?
Scinai Immunotherapeutics Ltd. trades on the Nasdaq under the ticker symbol SCNI.
What industry is Scinai Immunotherapeutics Ltd. in?
Scinai Immunotherapeutics Ltd. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Scinai Immunotherapeutics Ltd. headquartered?
Scinai Immunotherapeutics Ltd.'s business address on file with the SEC is in Jerusalem, Israel.
When does Scinai Immunotherapeutics Ltd.'s fiscal year end?
Scinai Immunotherapeutics Ltd.'s fiscal year ends on December 31.
How much revenue did Scinai Immunotherapeutics Ltd. report?
Scinai Immunotherapeutics Ltd. reported $1.3M in revenue for calendar year 2025, according to its SEC filings.